Cell Therapy News

Chimeric antigen receptor T-cell therapy can be administered at community centers and on an outpatient basis with proper preparation, education and resources, according to prospective study results.

I’m Luca Paruzzo, MD, a hematologist/oncologist working as a postdoctoral fellow at University of Pennsylvania under the mentorship of Marco Ruella, MD.

When Healio | Cell Therapy Next visited City of Hope in 2019, the institute boasted a robust cell therapy program, having treated 300 patients with the then-newly approved therapy.

Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably effective in real-world settings as they have been in pivotal clinical trials.

A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Chimeric antigen receptor T-cell therapy exhibited activity with minimal adverse effects for men with advanced prostate cancer, findings of a first-in-human trial showed.

A novel therapeutic approach may improve the persistence and functionality of chimeric antigen receptor T cells, helping to prevent relapse.

The FDA has granted fast track designation to topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated dermal toxicity, Azitra announced in a press release.